Kane Biotech Inc.
KNBIF
$0.03
$0.0024.38%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 304.61% | -345.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 304.61% | -345.16% | |||
| Cost of Revenue | 264.56% | -308.08% | |||
| Gross Profit | -151.85% | 245.95% | |||
| SG&A Expenses | -11.56% | 36.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.06% | 8.91% | |||
| Operating Income | -7.24% | -14.42% | |||
| Income Before Tax | -8.79% | -6.51% | |||
| Income Tax Expenses | 103.87% | -- | |||
| Earnings from Continuing Operations | -31.02% | 11.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.02% | 11.04% | |||
| EBIT | -7.24% | -14.42% | |||
| EBITDA | -6.81% | -36.04% | |||
| EPS Basic | -27.27% | -69.23% | |||
| Normalized Basic EPS | -12.50% | -100.00% | |||
| EPS Diluted | 33.33% | -223.08% | |||
| Normalized Diluted EPS | -12.50% | -100.00% | |||
| Average Basic Shares Outstanding | 0.14% | -46.46% | |||
| Average Diluted Shares Outstanding | 0.14% | -46.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||